Season 1 Episode 510
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Novo's amylin analog drug, cagrilintide, has shown a significant 11.8% weight loss in a phase III trial, with improved safety data to address past tolerability issues. The FDA is set to make a decision on the drug, with significant stakes for the company and the Barth Syndrome community. Additionally, Sarepta's DMD gene therapy is still being prescribed by doctors despite safety concerns, and new members have been appointed to the ACIP panel. Stealth Biotherapeutics is awaiting a verdict on their potential treatment for Barth Syndrome, while Sino Biological's high-throughput platform for AI-driven antibody discovery offers promise for advancing therapeutic candidates. Novo and Lilly are competing for market leadership in obesity treatment, while Sanofi and other pharma companies are pulling back from investments in the UK. The pharmaceutical industry is navigating uncertainty during turbulent times.
Published on 2 months, 4 weeks ago
If you like Podbriefly.com, please consider donating to support the ongoing development.
Donate